Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Apogee Therapeutics, Inc. (APGE)

77.82 +0.07 (+0.09%)
At close: May 28 at 4:00:01 PM EDT
78.32 +0.50 (+0.64%)
Pre-Market: 8:38:32 AM EDT
Trade APGE on Coinbase
Chart Range Bar
Loading chart for APGE
  • Previous Close 77.75
  • Open 77.87
  • Bid 56.74 x 200
  • Ask 99.77 x 200
  • Day's Range 77.11 - 79.43
  • 52 Week Range 34.34 - 95.32
  • Volume 1,226,957
  • Avg. Volume 934,135
  • Market Cap (intraday) 5.867B
  • Beta (5Y Monthly) 0.69
  • PE Ratio (TTM) --
  • EPS (TTM) -4.33
  • Earnings Date (est.) Aug 10, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 118.47

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

www.apogeetherapeutics.com

261

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 5/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

APGE
3.10%
S&P 500 (^GSPC)
10.49%

1-Year Return

APGE
113.79%
S&P 500 (^GSPC)
28.45%

3-Year Return

APGE
261.95%
S&P 500 (^GSPC)
79.85%

5-Year Return

APGE
261.95%
S&P 500 (^GSPC)
79.91%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -74.11M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-60M
-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

81.00
118.47 Average
77.82 Current
160.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/27/2026
Analyst Truist Securities
Rating Action Maintains
Rating Hold
Price Action Lowers
Price Target 83 -> 81

Statistics

View More

Valuation Measures

Annual
As of 5/28/2026
  • Market Cap

    5.87B

  • Enterprise Value

    4.81B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.67

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -19.00%

  • Return on Equity (ttm)

    -28.47%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -274.62M

  • Diluted EPS (ttm)

    -4.33

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.06B

  • Total Debt/Equity (mrq)

    0.64%

  • Levered Free Cash Flow (ttm)

    -142.58M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

77.82 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: